Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children

Vaccine. 2006 Sep 29;24(40-41):6437-45. doi: 10.1016/j.vaccine.2006.05.089. Epub 2006 Jun 13.

Abstract

As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at 18,644 US dollars. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to 98,734 US dollars.

MeSH terms

  • Child
  • Costs and Cost Analysis
  • Eye Diseases / congenital
  • Eye Diseases / economics
  • Eye Diseases / therapy
  • Follow-Up Studies
  • Hearing Disorders / congenital
  • Hearing Disorders / economics
  • Hearing Disorders / therapy
  • Heart Defects, Congenital / economics
  • Heart Defects, Congenital / therapy
  • Humans
  • Infant, Newborn
  • Nervous System Diseases / congenital
  • Nervous System Diseases / economics
  • Nervous System Diseases / therapy
  • Oman
  • Rubella Syndrome, Congenital / drug therapy
  • Rubella Syndrome, Congenital / economics*
  • Rubella Syndrome, Congenital / rehabilitation
  • Rubella Syndrome, Congenital / therapy*
  • Rubella virus*
  • Speech Disorders / economics
  • Speech Disorders / therapy
  • Time Factors